TYRA-430 for advanced liver cancer and other solid tumors
Part of Cancer, Digestive system clinical trials.
This trial tests an oral drug called TYRA-430 for people with advanced liver cancer (HCC) or other solid tumors that have changes in the FGF/FGFR pathway. It aims to see how safe the drug is and whether it can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need to have advanced liver cancer (HCC) or another solid tumor with a specific change in the FGF/FGFR pathway.
- You must have already had at least one standard treatment for your cancer.
- You should be able to swallow pills and have good organ function (like liver and kidneys).
- You cannot have serious heart problems, untreated brain tumors, or certain stomach issues that affect swallowing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill called TYRA-300 for people with low-grade bladder cancer that hasn't spread into the muscle layer. The pill targets a specific gene change (FGFR3) found in the tumor. The goal is to see if it can slow or shrink the cancer.
This Phase 2 study tests a treatment aimed at specific FGFR (a cancer-growth signal) changes found in your tumor. It may help people whose cancer has spread, cannot be removed, or has stopped responding to standard treatment.
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
This trial tests an experimental cell treatment called HRYZ-T102 TCR-T for people with advanced liver cancer or other solid tumors that make a protein called AFP. The treatment uses your own immune cells, modified in a lab to target and kill cancer cells.
This trial tests a new tablet, TYK-00540, alone or with another drug, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Metastatic Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.